Ποια είναι η τιμή για TMS Co., Ltd. (4891)

Η τιμή για TMS Co., Ltd. (4891) είναι $0.73072946

Ποια είναι η κεφαλαιοποίηση αγοράς για TMS Co., Ltd. (4891)

Η κεφαλαιοποίηση αγοράς για TMS Co., Ltd. (4891) είναι $33.30M

TMS Co., Ltd. (4891) Διαίρεση Μετοχών

Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.